Ludmila V. Bembeeva
A5002712469- Advanced Breast Cancer Therapies
- Breast Cancer Treatment Studies
- PI3K/AKT/mTOR signaling in cancer
- HER2/EGFR in Cancer Research
City Clinical Oncology Center
2022-2025
Background. Given the high prevalence of hormone-sensitive breast cancer in Russia and around world, it is extremely important to address issue indications for neoadjuvant (NACT) or adjuvant chemotherapy, as well scope regimens treatment. The article presents results our own study, considers problems toxicity tolerability dose-dense standard NACT regimens. Aim. To study Materials methods. prospective included 109 patients. 53 patients received preoperative treatment, 56 – regimen. Results....
Background. By 2020, breast cancer (BC) has become the most frequent malignancy in world. The common type of BC is HR+/HER2-negative cancer,2540% which harbors PIK3CA mutations that affect catalytic subunit PI3K protein. alterations are actionable, as such neoplasms can be treated with a combination fulvestrant and inhibitor alpelisib. As have an extremely versatile effect on characteristics tumor cell, numerous associations various clinico-pathological traced.
 Aim. Our aim was to...